Praxis Precision Medicines, Inc. (PRAX)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow PRAX in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on PRAX and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
PRAX at a glance
Key statistics
$7.38B
Market capitalization
- Previous close
- $264.49
- Open
- $264.99
- Day range
- $260.40 – $271.88
- Volume
- 204.6K
- Average volume (30 sessions)
- 537.6K
- Shares outstanding
- 27.92M
- Earnings per share
- $(12.15)
- Price / book
- 5.5
- Beta (1 year, vs SPY)
- 1.26
Where the price sits in its year
52-week range
45% of the range
- Below the 52-week high
- -33.5%
- Above the 52-week low
- +69.0%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $269.93-2.0%
- 50-day average
- $317.81-16.8%
- 200-day average
- $315.42-16.1%
Between the conventional 30 and 70 bands.
+8.7%
1 week
-11.5%
1 month
-15.3%
3 months
-10.3%
Year to date
+39.2%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with PRAX
PRAX on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on PRAX.
See the plans →
Every planScreen names like PRAX
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on PRAX
Put PRAX on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on PRAX
See whether there is an open premium alert on PRAX, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
PRAX headlines
- Why Is Praxis Precision Stock Soaring Tuesday?
Benzinga · Apr 14, 2026
- Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
GlobeNewswire Inc. · Apr 6, 2026
- Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
GlobeNewswire Inc. · Jan 8, 2026
- Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
GlobeNewswire Inc. · Jan 6, 2026
- Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Benzinga · Jan 6, 2026
- Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
GlobeNewswire Inc. · Dec 29, 2025
- Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On?
Benzinga · Dec 5, 2025
- Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
GlobeNewswire Inc. · Oct 16, 2025
SEC Form 4, most recent first
Insider filings
Souza Marcio
−2.6K
Chief Executive Officer, Director · Gift
· Jul 8, 2026
Souza Marcio
−20.5K
Chief Executive Officer, Director · Gift
· Jul 8, 2026
DeSimone Jill
−320
Director · Open-market sale
$97.70K · Jun 24, 2026
DeSimone Jill
−8.6K
Director · Option exercise
· Jun 24, 2026
DeSimone Jill
−837
Director · Open-market sale
$264.25K · Jun 24, 2026
DeSimone Jill
−2.9K
Director · Open-market sale
$890.20K · Jun 24, 2026
DeSimone Jill
−3.0K
Director · Option exercise
· Jun 24, 2026
DeSimone Jill
−999
Director · Open-market sale
$309.07K · Jun 24, 2026
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Employees
- 10,998
- Listed since
- Oct 16, 2020
- Website
- praxismedicines.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.